015: Subtype Specific Stratification and Targeting of Pancreatic Adenocarcinoma

HIPO Investigator:

Prof. Andreas Trummp

Dr. Martin Sprick

Prof. Roland Eils

Prof. Wilko Weichert

Dr. Jens Werner


Supported by: HIPO/POP

Entity: Pancreatic Adenocarcinoma (PDAC)


Noll EM et al.; CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma, Nat. Med. 2016

Espinet E et al.; Cellular deconvolution and expression analysis of Stromal and Epithelial cells directly isolated from human Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatology 2017

DKFZ Logo 3zu Research en Black Blue sRGB

4c nctlogo 2009

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok Decline